Secukinumab
- PDF / 169,885 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 52 Downloads / 179 Views
1 S
Paradoxical effect in the form of new-onset inflammatory bowel disease: case report A 45-year-old woman experienced a paradoxical effect in the form of new-onset inflammatory bowel disease (IBD) during treatment with secukinumab for ankylosing spondylitis. The woman, who was diagnosed with ankylosing spondylitis 8 years earlier, had been receiving long-term therapy with unspecified NSAIDs and certolizumab pegol at therapeutic doses. Due to persistent symptoms, certolizumab pegol was replaced with secukinumab 150 mg/week for 4 weeks, followed by 150 mg/4 weeks [route not stated]. However, during week 6 of secukinumab therapy, she was hospitalised due to abdominal pain, increased bowel movements, diarrhoea, tenesmus and a weight loss of 3kg over 20 days. An abdominal examination revealed increased bowel sounds and widespread tenderness in the abdomen. Laboratory test results were notable for decreased haemoglobin levels, increased WBC count, ESR and CRP, and enrichment of erythrocytes and leucocytes in microbiological examination of stool. Flexible colonoscopy revealed aphthous ulcers and erosions in the distal segment of the terminal ileum, deep ulcers in the colon wall and mucosa for each segment, and normal looking protected areas. Histologic evaluation of the biopsy was consistent with focal active colitis and chronic active ileitis. Therefore, a diagnosis of new-onset IBD as a paradoxical reaction to secukinumab was established. Secukinumab was discontinued, and the woman started receiving methylprednisolone. After 5 days of treatment with methylprednisolone, her symptoms improved, and within 3 weeks, all abnormal clinical findings resolved. Yazisiz V, et al. Onset of inflammatory bowel disease following interleukin-17A inhibitor treatment. Archives of Rheumatology 35: 300-302, No. 2, Jun 2020. Available from: 803498183 URL: http://doi.org/10.46497/ArchRheumatol.2020.7555
0114-9954/20/1819-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 29 Aug 2020 No. 1819
Data Loading...
